

DOCKET NUMBER
PETITION RULE PRM 35-9
(54 FR 38239)
NuPATH, P.C.

99

'89 OCT 30 A9:58

R. J. RETTENMAIER, M.D.
D. R. SAMUELSON, M.D.
R. C. WATSON, M.D.
J. W. SNOW, JR., M.D.
J. G. LYDAY, M.D.

OFFICE OF THE SECRETARY
DOCKET NUMBER PRM-35-9

October 24, 1989

Secretary of the Commission
U. S. Nuclear Regulatory Commission
Docketing and Service Branch, Docket #PRM-35-9
Washington, D.C. 20555

Dear Mr. Secretary:

I am writing to express my strong support for the Petition For Rule Making filed by the American College of Nuclear Physicians and the Society of Nuclear Medicine. I am a practicing nuclear medicine physician at McDonough District Hospital in Macomb, IL. I am deeply concerned over the revised 10CFR35 Regulations (effective April, 1987), governing the medical use of by-product material as they significantly impact on my ability to practice high quality nuclear medicine/nuclear pharmacy and are preventing me from providing optimized care to individual patients.

The NRC should recognize that the FDA does allow, and often encourages, other clinical uses of approved drugs. It actively discourages the submission of physician sponsored IND's that describe new indications for approved drugs. The package insert was never intended to prohibit physicians from deviating from it for other indications; on the contrary, such deviation is necessary for growth and developing new diagnostic and therapeutic procedures. In many cases, manufacturers will never go back to the FDA to revise a package insert to include a new indication because it is not required by the FDA and there is simply no economic incentive to do so.

Currently, the regulatory provisions in Part 35 (35.100, 35.200, 35.300 and 33.17 (a) (4)) do not allow practices which are legitimate and legal under FDA regulations and state medicine and pharmacy laws. These regulations therefore inappropriately interfere with the practice of medicine, which directly contradicts the NRC's Medical Policy statement against such interference.

8911020083 891024
PDR PRM
35-9

PDR

McDONOUGH DISTRICT HOSPITAL
BURLINGTON MEDICAL CENTER

MACOMB, ILLINOIS 61455
BURLINGTON, IOWA 52601

(309) 837-2368
(319) 753-3648


AS 10

The NRC should not strive to construct proscriptive regulations to cover all aspects of medicine, nor should it attempt to regulate pharmaceutical use. Instead, the NRC should rely on the expertise of the FDA, state boards of pharmacy, state boards of medical quality assurance, the Joint Commission on accreditation of health care organizations, radiation safety committees, institutional quality assurance review procedures, and most importantly, the professional judgement of physicians and pharmacists who have been well trained to administer and prepare these materials.

Since the NRC's primary regulatory focus appears to be based on the unsubstantiated assumption that midadministrations, particularly those involving diagnostic radiopharmaceuticals, pose a serious threat to public health and safety, I strongly urge the NRC to pursue a comprehensive study by a reputable scientific panel, such as the National Academy of Sciences or the NCRP, to assess the radiobiological effects of midadministrations from nuclear medicine diagnostic and therapeutic studies. I firmly believe that the results of such a study will demonstrate that the NRC's efforts to impose more and more stringent regulations are unnecessary and not cost effective in relation to the extremely low health risks of these studies.

In closing, I strongly urge the NRC to adopt the ACNP/SNM Petition for Rule Making as expeditiously as possible.

Sincerely,



R. C. Watson, M.D.
Nuclear Medicine
Physician, McDonough
District Hospital,
Macomb, IL

RCW/mh